Lab Genomics Pays $1.25M to Settle Kickback Claims
Clinical laboratories paying marketers by referral volume face False Claims Act exposure, as this settlement illustrates.
Updated on Nov. 6, 2026 in Healthcare
Live Poll
Do you trust that your doctor's lab test recommendations are based only on your medical needs?
Lab Genomics LLC, a clinical laboratory based in Fountain Valley, California, and its owner Leena Dalal agreed to pay $1.25 million to resolve False Claims Act kickback allegations. The settlement was announced by the Justice Department on November 6, 2026, and concerns clinical laboratory test referrals.
Why it matters
The allegations center on commissions allegedly paid to marketers to induce laboratory test orders, a practice that exposes labs and their referral partners to federal liability. For healthcare operators, the case is a reminder that compensation structures tied to referral volume carry significant enforcement risk.
The $1.25 million settlement resolves allegations that three independent contractor marketers received value- and volume-based commissions from January 2020 through September 2022. Of the total, $225,000 goes to the relators who filed the qui tam suit, and the extraction does not specify whether the settlement includes an admission of liability.
The players
Lab Genomics LLC
A clinical laboratory based in Fountain Valley, California, whose test referrals are the subject of the settlement.
Leena Dalal
Owner of Lab Genomics LLC, who agreed to the settlement alongside the company.
U.S. Attorney's Office for the Eastern District of California
The federal prosecutor's office with jurisdiction over the lawsuit and settlement.
The details
Lab Genomics allegedly paid commissions to marketers based on the value and volume of laboratory test referrals. The company allegedly structured invoices so the commission payments appeared as flat fees, which is the mechanism the government alleges masked the payments. The settlement resolves certain allegations in a qui tam lawsuit filed by Sunil Wadhwa and Ken Newton, and the United States previously resolved similar allegations against Admera Health LLC and NEXT Bio-Research Services LLC.
Timeline
January 2020 through September 2022: alleged commission payments to three marketers occurred.
November 6, 2026: Justice Department announced the settlement.
Market Landscape
The settlement follows earlier federal resolutions against Admera Health LLC and NEXT Bio-Research Services LLC over similar alleged referral-kickback conduct. It signals that federal enforcement against commission-based laboratory marketing arrangements is a continuing pattern rather than an isolated case.
Healthcare operators should review any marketer or referral-partner agreements that tie compensation to test volume or value, particularly where invoices may be structured as flat fees. Businesses with such arrangements should consult qualified counsel to assess exposure under the False Claims Act.
The takeaway
The enforcement pattern in this case points to commission structures tied to referral volume as a recurring compliance risk for laboratories and their marketing partners. Operators should review referral-compensation contracts and invoice formats with qualified counsel, and track any further Justice Department resolutions involving clinical laboratories.
Further reading
For broader context on federal enforcement in medical referrals, see the Healthcare section.
Source note: This article includes information reported by The United States Department of Justice.
Live Poll
Do you trust that your doctor's lab test recommendations are based only on your medical needs?
